Irish Body Urges Simplified Route For Value Added Medicines
Highlights Need To Bring Ireland In Line With Other Major European Countries
Medicines for Ireland has called for a change of the “cumbersome, complex, costly and unclear regulatory processes” for value added medicines in Ireland. In conjunction with Medicines for Europe, the Irish association has published a report on the authorities to encourage innovation around existing molecules in the form of repurposing, reformulation and combination of therapies.
You may also be interested in...
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Positive trial results for dexamethasone in treating COVID-19 patients demonstrate the potential of repurposing existing generic medicines to fight the coronavirus pandemic.
US representatives Abigail Spanberger and David McKinley have introduced bipartisan legislation to create an emergency supply of active ingredients used in vital generics and to incentivize domestic manufacturing of these ingredients. The move has garnered support from many industry leaders.